Cyrus Harmon Sells 20,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock in a transaction on Friday, June 28th. The stock was sold at an average price of $10.77, for a total value of $215,400.00. Following the completion of the sale, the director now directly owns 761,283 shares of the company’s stock, valued at approximately $8,199,017.91. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Cyrus Harmon also recently made the following trade(s):

• On Monday, June 3rd, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $10.93, for a total value of $54,650.00.
• On Friday, May 31st, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.41, for a total value of $141,150.00.
• On Monday, May 6th, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $10.92, for a total value of $54,600.00.
• On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.51, for a total value of $142,650.00.

Olema Pharmaceuticals Trading Down 6.6 %

NASDAQ OLMA traded down $0.73 on Tuesday, hitting $10.41. 714,306 shares of the company traded hands, compared to its average volume of 891,102. The company has a market capitalization of $582.23 million, a price-to-earnings ratio of -5.15 and a beta of 2.06. The business’s 50 day moving average price is $10.86 and its 200-day moving average price is $12.01. Olema Pharmaceuticals, Inc. has a 52-week low of $7.78 and a 52-week high of $17.79.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Wednesday, May 8th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.03). As a group, sell-side analysts predict that Olema Pharmaceuticals, Inc. will post -2.3 earnings per share for the current year.

Hedge Funds Weigh In On Olema Pharmaceuticals

Large investors have recently made changes to their positions in the business. First Light Asset Management LLC purchased a new position in shares of Olema Pharmaceuticals in the fourth quarter valued at about $8,854,000. Swiss National Bank purchased a new position in shares of Olema Pharmaceuticals in the fourth quarter valued at about $906,000. Perceptive Advisors LLC purchased a new position in shares of Olema Pharmaceuticals in the fourth quarter valued at about $7,574,000. Victory Capital Management Inc. lifted its position in shares of Olema Pharmaceuticals by 879.6% in the fourth quarter. Victory Capital Management Inc. now owns 621,527 shares of the company’s stock valued at $8,720,000 after acquiring an additional 558,077 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Olema Pharmaceuticals by 1.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,715,420 shares of the company’s stock valued at $24,069,000 after acquiring an additional 21,420 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OLMA has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Tuesday, June 4th. The Goldman Sachs Group initiated coverage on Olema Pharmaceuticals in a research note on Tuesday, April 2nd. They issued a “buy” rating and a $24.00 price target on the stock. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Olema Pharmaceuticals has an average rating of “Buy” and an average price target of $22.00.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.